Sun Pharma Q4 FY25: Strong Growth & Dividends

  Published 1 year ago

Sun Pharmaceutical reported strong Q4 FY25 results with a 15.6% YoY jump in PBT and a 22.4% rise in EBITDA. India formulations grew 13.6%, while US formulations saw a slight decline. A final dividend of Rs 5.50 per share was recommended.

  • PBT up 15.6% YoY to Rs 3,254.35 crore.
  • EBITDA margin at 28.7% with 22.4% growth.
  • Final dividend of Rs 5.50/share proposed.

You might like these

Meta Eyes $10B+ AI Investment in Scale AI

India Core Sector Grows 1.7%

Markets Dip as IT Drags, Trade Talks Stall

L&T Wins Major Orders Across Units

Biocon Expands Tablet Production with $30M OSD Plant

Jash Expands with New Plant Deal

Nestlé India Profit Falls 12% in Q1

News that matters the most ⚡